Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Background. Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Solomkin, Joseph, Hershberger, Ellie, Miller, Benjamin, Popejoy, Myra, Friedland, Ian, Steenbergen, Judith, Yoon, Minjung, Collins, Sylva, Yuan, Guojun, Barie, Philip S., Eckmann, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Articles and Commentaries
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412191/
https://ncbi.nlm.nih.gov/pubmed/25670823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ097
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados